Lead Product(s) : Naronapride
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Dr. Falk Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Renexxion and Dr. Falk Expand Phase 2b Study of Naronapride in Gastroparesis
Details : ATI 7505 (naronapride) is a potential best-in-class oral, locally acting pan-GI prokinetic, that acts as 5-HT4R agonist and D2R antagonist. It is being evaluated for the treatment of Gastroparesis.
Product Name : ATI-7505
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 13, 2024
Lead Product(s) : Naronapride
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Dr. Falk Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naronapride
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Dr. Falk Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Renexxion and Dr. Falk Announce FDA Clearance for Naronapride in Gastroparesis
Details : ATI 7505 (naronapride) is a potential best-in-class oral, locally acting pan-GI prokinetic, that acts as 5-HT4 receptor agonist and D2 receptor antagonist. It is being evaluated for Gastroparesis.
Product Name : ATI-7505
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2024
Lead Product(s) : Naronapride
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Dr. Falk Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naronapride
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-7505 (naronapride) is a late-development stage, pan-GI prokinetic. It is a highly selective 5HT-4 agonist and D2 antagonist, is being developed for GI motility in cystic fibrosis.
Product Name : Naronapride
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2023
Lead Product(s) : Naronapride
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifamycin
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : RedHill Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial investigated the efficacy and safety of two doses of Rifamycin SV-MMX 600mg against placebo after a 2-week course of treatment followed by a 3 months follow-up.
Product Name : Aemcolo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2021
Lead Product(s) : Rifamycin
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : RedHill Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naronapride
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Dr. Falk Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
Details : The collaboration with Dr. Falk Pharma will serve as a catalyst to Renexxion advancing Naronapride, a drug candidate which possesses combination of both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties to patients with G...
Product Name : ATI-7505
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 10, 2021
Lead Product(s) : Naronapride
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Dr. Falk Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Rifamycin Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosmo Announces Successful Outcome of Rifamycin 600MG Phase II Trial in IBS-D
Details : Rifamycin SV MMX (rifamycin sodium) is a DNA-directed RNA polymerase inhibitor antibiotic, being evaluated for the treatement of irritable bowel syndrome with diarrhea.
Product Name : Rifamycin SV MMX
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 11, 2021
Lead Product(s) : Rifamycin Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifamycin Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Dr. Falk Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cosmo Expands Agreement with Dr. Falk Pharma for Rifamycin SV MMX
Details : Cosmo expanded its existing license agreement with Dr. Falk Pharma to include Rifamycin SV MMX (Rifamycin Sodium) in the new 600mg formulation currently tested in the IBS-D indication.
Product Name : Rifamycin SV MMX
Product Type : Antibiotic
Upfront Cash : Undisclosed
November 19, 2020
Lead Product(s) : Rifamycin Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Dr. Falk Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement